Aligos Therapeutics (ALGS) announced the appointment of Kieron Wesson, PhD as Vice President, Head of Chemistry Manufacturing Controls, effective immediately. Prior to joining Aligos Therapeutics, Dr. Wesson served in positions of increasing responsibility, including as the Head of CMC and Supply Chain at Kezar Life Sciences and AN2 Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics appoints Laura Kavanaugh as VP, head of legal
- Aligos Therapeutics presents data at EASL Congress 2025
- Aligos Therapeutics Reports Strong Q1 2025 Progress
- Aligos Therapeutics reports Q1 EPS ($2.11), consensus ($3.15)